Yervoy (ipilimumab) / Ono Pharma, BMS  >>  Phase 1
Welcome,         Profile    Billing    Logout  

120 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yervoy (ipilimumab) / BMS
CRIMI, NCT03844256 / 2017-004751-23: A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the Study

Recruiting
1b
50
Europe
nivolumab 480mg, mitomycin-c 12mg/m2 IV, capecitabine 750mg/m2, radiotherapy 40Gy in 20 fractions of 2Gy, nivolumab 3mg/kg, ipilimumab 1mg/kg, nivolumab 1mg/kg, ipilimumab 3mg/kg
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Bristol-Myers Squibb
Urinary Bladder Cancer, Invasive Bladder Cancer
07/24
07/26
CRETI-NH, NCT00586391: CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL

Active, not recruiting
1
14
US
CD19CAR-28-zeta T cells, Ipilimumab, Yervoy
Baylor College of Medicine, The Methodist Hospital Research Institute, Center for Cell and Gene Therapy, Baylor College of Medicine
B Cell Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia
07/14
07/29
NCT01860430: A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer

Active, not recruiting
1
18
US
Cetuximab/IMRT Plus Ipilimumab
Robert Ferris, National Cancer Institute (NCI)
Cancer of Head and Neck
07/16
03/18
NCT01935921: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Completed
1
19
US
Cetuximab, Cetuximab Biosimilar CDP-1, Cetuximab Biosimilar CMAB009, Cetuximab Biosimilar KL 140, Chimeric Anti-EGFR Monoclonal Antibody, Chimeric MoAb C225, Chimeric Monoclonal Antibody C225, Erbitux, IMC-C225, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
10/16
07/18
NCT01938703: BRAF-MEK INHIBITORS IN SEQUENCE WITH IPILIMUMAB FOR BRAF MUTANT MELANOMA

Recruiting
1
40
US
Dabrafenib, Trametinib, Ipilimumab
Dana-Farber Cancer Institute, National Cancer Institute (NCI), National Institutes of Health (NIH)
Malignant Melanoma, Cutaneous Neoplasms
12/16
08/19
NCT02308943: Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Not yet recruiting
1
90
US
Cabozantinib S-malate, BMS-907351, Cometriq, XL184, Nivolumab, anti-PD-1 human monoclonal antibody MDX-1106, BMS-936558, MDX-1106, ONO-4538, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Adult Solid Neoplasm, Malignant Reproductive System Neoplasm, Malignant Urinary System Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Progressive Neoplastic Disease, Recurrent Bladder Carcinoma, Recurrent Urethra Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma
08/17
 
NCT00790010: Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Checkmark Data
May 2011 - May 2011: Data
Completed
1
46
US
Bevacizumab Plus Ipilimumab Cohort 1, Bevacizumab- also known as Avastin, Ipilimumab-also known as MDX-010 or MDX-101 & marketed as Yervoy, Bevacizumab Plus Ipilimumab Cohort 2, Bevacizumab Plus Ipilimumab Cohort 3, Bevacizumab Plus Ipilimumab Cohort 4
Dana-Farber Cancer Institute, Genentech, Inc., Bristol-Myers Squibb
Melanoma
06/18
06/18
OpACIN, NCT02437279: Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients

Checkmark Data from OpACIN study in combination with Yervoy
Jun 2020 - Jun 2020: Data from OpACIN study in combination with Yervoy
Checkmark Results from OpACIN study in combination with Yervoy
Dec 2018 - Dec 2018: Results from OpACIN study in combination with Yervoy
Active, not recruiting
1
20
Europe
Surgery of the tumor, Infusion with ipilimumab 3 mg/kg q3wks, Infusion with nivolumab 1 mg/kg q3wks
The Netherlands Cancer Institute, Bristol-Myers Squibb
Stage III Skin Melanoma
06/18
06/25
NCT02532205: A Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Not yet recruiting
1
60
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma, Advanced Solid Malignancies
12/18
 
NCT02812524: Ipilimumab for Head and Neck Cancer Patients

Active, not recruiting
1
18
US
Intratumoral Ipilimumab, Yervoy, BMS734016, MDX-010
Providence Health & Services, Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck
09/19
12/24
TICIMEL, NCT03293784: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma

Completed
1
33
Europe
Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab, Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
Institut Claudius Regaud
Melanoma
12/19
08/23
NCT02210117: Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

Active, not recruiting
1
104
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Biopsy, Bx, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Metastasectomy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer AJCC v7
11/25
11/25
NCT01176474: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
1
73
US
NY-ESO-1 157-165 (165V), NSC 717388, peptide vaccine, NY-ESO-1, ESO-165V Peptide, Nivolumab, BMS-936558, NSC 748726, Anti PD-1, antibody, MDX-1106, Immunotherapy, HMA, gp100:280-288 (288V), NSC 683473, Peptide, g9-288-9V Peptide, Montanide ISA 51 vegetable grade (VG), NSC 737063, Ipilimumab, NSC 732442, Apheresis Procedure
H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute (NCI), Medarex, Bristol-Myers Squibb
Melanoma (Skin)
08/20
01/23
ETCTN-9844, NCT02453620: Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Active, not recruiting
1
57
US
Biopsy, BIOPSY_TYPE, Bx, Blood Sample, Blood, Blood Draw, Blood Specimen, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Entinostat, HDAC inhibitor SNDX-275, MS 27-275, MS 275, MS-275, MS275, SNDX 275, SNDX-275, SNDX275, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
04/21
09/25
CA209-991, NCT03507699: Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

Completed
1
19
RoW
Liver radiation therapy, Liver radiosurgery, Nivolumab Injection [Opdivo], Ipilimumab Injection [Yervoy], CMP-001
Sheba Medical Center, Checkmate Pharmaceuticals, Bristol-Myers Squibb
Colorectal Neoplasms Malignant, Liver Metastases
08/21
05/22
RACIN, NCT03728179: in Patients With Advanced TIL-negative Solid Tumors

Completed
1
40
Europe
Low dose irradiation + Nivolumab + Ipilimumab or Cyclophosphamide + Aspirin/Celecoxib
Centre Hospitalier Universitaire Vaudois
Solid Tumor, Adult
10/23
10/23
NCT03425292: A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Completed
1
49
US
Temozolomide, temodar, conformal brain radiation therapy, Nivolumab, opdivo, Ipilimumab, yervoy, Bevacizumab, avastin, 5-day Temozolomide, Lomustine, CCNU, Nivolumab monotherapy
Saint John's Cancer Institute
Newly Diagnosed High Grade Glioma
09/22
10/23
NCT04868760: A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Active, not recruiting
1
148
RoW
Ipilimumab, IBI310
Innovent Biologics (Suzhou) Co. Ltd.
Healthy Subjects
09/22
12/22
NCT03816332: Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

Active, not recruiting
1
12
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius
National Cancer Institute (NCI)
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Basal Cell Carcinoma, Metastatic Melanoma, Metastatic Merkel Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Unresectable Basal Cell Carcinoma, Unresectable Melanoma, Unresectable Merkel Cell Carcinoma
10/22
09/24
NCT03068624: Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Active, not recruiting
1
34
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous CD8+ SLC45A2-specific T Lymphocytes, Autologous SLC45A2-specific CTLs, Autologous SLC45A2-specific Cytotoxic T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
12/22
07/25
SQZ-PBMC-HPV-101, NCT04084951: Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Completed
1
30
Europe, Canada, US
SQZ-PBMC-HPV, Atezolizumab, Ipilimumab, Nivolumab
SQZ Biotechnologies
Adult Solid Tumor
02/23
02/23
da VINci, NCT03784040: Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.

Recruiting
1
40
RoW
OTSGC-A24, Nivolumab, Ipilimumab
National University Hospital, Singapore, OncoTherapy Science, Inc., Bristol-Myers Squibb
Gastric Cancer
03/23
03/24
NCT04721301: Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

Completed
1
50
Europe
Nivolumab plus Ipilimumab plus Maraviroc
University Hospital Heidelberg, German Cancer Research Center
Colorectal Cancer Metastatic, Pancreatic Cancer Metastatic
03/23
03/23
NCT04610658: Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC

Terminated
1
9
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Lurbinectedin
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb, Jazz Pharmaceuticals
Small-cell Lung Cancer, Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
03/23
03/23
NCT03493932: Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Completed
1
21
US
Nivolumab, BMS-986016
National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma
04/23
06/23
Glaspy BMS CA209-9ET Breast, NCT04185311: Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Terminated
1
6
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
Jonsson Comprehensive Cancer Center, National Cancer Institute (NCI)
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, HER2/Neu Negative, Invasive Ductal Carcinoma, Not Otherwise Specified, Progesterone Receptor Negative, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
05/23
05/23
NCI-2016-01300, NCT02879695: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Active, not recruiting
1
24
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Blinatumomab, AMG 103, Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody, Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103, Blincyto, MEDI-538, MEDI538, MT-103, MT103, Bone Marrow Aspiration and Biopsy, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
National Cancer Institute (NCI)
Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
05/23
09/24
NCT04518046: Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Completed
1
22
US
Sitravatinib, MGCD516, Nivolumab, OPDIVO, Ipilimumab, YERVOY
Mirati Therapeutics Inc.
Clear-Cell Renal Cell Carcinoma
06/23
06/23
NCT03978611: A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Terminated
1
11
Europe, Canada, US
Relatlimab, BMS-986016, Ipilimumab
Bristol-Myers Squibb
Melanoma
07/23
07/23
SCANDIUM II, NCT04463368: Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases

Active, not recruiting
1
18
Europe
Isolated hepatic perfusion, Ipilimumab, Nivolumab
Vastra Gotaland Region, Bristol-Myers Squibb
Uveal Melanoma, Liver Metastases
08/24
12/24
EP-NECAs, NCT05262556: NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Active, not recruiting
1
15
US
NP-101 (TQ Formula), Black seed oil capsules, Nivolumab (3mg/kg), Opdivo, Ipilimumab (1mg/kg), Yervoy
Amr Mohamed MD, Novatek Pharmaceuticals
Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
10/24
04/26
NCT04429321: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Terminated
1
1
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, bland embolization, trans-arterial embolization
Abramson Cancer Center at Penn Medicine
Renal Cell Carcinoma, Renal Cell Carcinoma Stage IV
01/24
01/24
HIPANIV, NCT04823403: Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Recruiting
1
27
Europe
Nivolumab, Ipilimumab
Gustave Roussy, Cancer Campus, Grand Paris
Hepatocellular Carcinoma
11/22
11/24
NEXUS, NCT04850755: A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Recruiting
1
30
RoW
Selinexor in combination with nivolumab and ipilimumab
National University Hospital, Singapore
Advance Solid Malignancies, Metastatic Solid Malignancies
11/23
11/24
GlitIpNi, NCT03233152: Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma

Active, not recruiting
1
110
Europe
Ipilimumab (YervoyTM, 50 mg/10 mL solution), Nivolumab (OpdivoTM, 40 mg/4 mL solution), Nivolumab (OpdivoTM, 40 mg/4mL solution)
Universitair Ziekenhuis Brussel
Glioblastoma
11/23
11/23
NCT06159101: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Recruiting
1
304
RoW
HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group, US-sourced ipilimumab group
Shanghai Henlius Biotech
Healthy Male Volunteers
05/24
05/24
NCT02922764: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer

Checkmark From a trial for solid tumors
Jun 2020 - Jun 2020: From a trial for solid tumors
Active, not recruiting
1
146
US
RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
Inspirna, Inc.
Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
09/24
09/24
NCT03388632: Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Recruiting
1
50
US
rhIL-15, Ipilimumab, Nivolumab
National Cancer Institute (NCI)
Metastatic Solid Tumors, Treatment-Refractory Cancers
12/24
12/24
P30CA033572, NCT03829111: CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

Completed
1
30
US
Clostridium butyricum CBM 588 Probiotic Strain, C. butyricum CBM 588 Probiotic Strain, C. butyricum MIYAIRI Strain, C. butyricum Strain MIYAIRI 588, CBM 588, CBM588, Clostridium butyricum MIYAIRI 588, Clostridium butyricum MIYAIRI 588 Probiotic Strain, MIYAIRI 588, MIYAIRI 588 Strain of C. butyricum, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
12/23
12/23
NCT03373188: VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Completed
1
10
US
Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Surgery
Emory University, Vaccinex Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
10/21
10/21
NCT03769155: VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Active, not recruiting
1
41
US
Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, VX15/2503, moAb VX15/2503, Pepinemab, Surgery
Emory University, Bristol-Myers Squibb, Vaccinex Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
12/23
12/32
NCI-2018-03329, NCT03798639: Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer

Completed
1
7
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
Claire Verschraegen
Merkel Cell Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8
12/22
12/22
NCT04003649: IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Recruiting
1
60
US
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells, IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells, IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Refractory Glioblastoma
07/24
07/25
NCT04362839: Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
1
39
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Regorafenib, BAY 73-4506, Stivarga
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Colon Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Colon Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Colon Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Rectal Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Rectal Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Stage IVC Rectal Cancer AJCC v8
12/24
12/24
NCT03929029: Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Active, not recruiting
1
20
US
Nivolumab, Opdivo, NeoVax plus Montanide, Ipilimumab, Yervoy
Dana-Farber Cancer Institute, National Cancer Institute (NCI)
Melanoma
12/22
09/28
NCT04606316: Surgical Nivolumab And Ipilimumab For Recurrent GBM

Active, not recruiting
1
63
US
Nivolumab-Placebo, Nivolumab, Opdivo, Ipilimumab-Placebo, Ipilimumab, Yervoy, Surgery, Resection
Patrick Wen, MD, Bristol-Myers Squibb
Glioblastoma, GBM, Glioblastoma Multiforme, Grade IV Astrocytoma
12/24
12/24
NCT04697576: Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Recruiting
1
36
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Quadrivalent Inactivated Influenza Vaccine, Fluzone Quadrivalent, Fluzone Quadrivalent Influenza Vaccine, QIV, Quadrivalent Influenza Vaccine, Resection, Surgical Resection, Nivolumab + Relatlimab, Opdualag
Carlo Contreras
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
12/23
12/25
CPIT-002, NCT02846376: Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

Terminated
1
8
US
Nivolumab, Bristol-Myers Squibb (BMS-936558), Ipilimumab, BMS-734016
Hackensack Meridian Health
Acute Myeloid Leukemia and Myelodysplastic Syndrome
12/23
12/23
NCT04290546: CIML NK Cell in Head & Neck Cancer

Active, not recruiting
1
11
US
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, cytokine induced memory-like natural killer, Ipilimumab, CTLA-4 inhibitor, Cetuximab, EGFR inhibitor
Dana-Farber Cancer Institute, Altor BioScience, Bristol-Myers Squibb, Miltenyi Biomedicine GmbH
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
09/24
12/24
NCT04840589: Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Recruiting
1
66
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
01/26
01/26
NCT06508463: Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Recruiting
1
20
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Oncolytic VSV-hIFNbeta-NIS, Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Voyager-V1, VSV-expressing hIFNb and NIS, VSV-hIFNb-NIS, VSV-hIFNbeta-NIS, VV1, VSV-hIFNβ-NIS, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Cemiplimab, 1801342-60-8, Cemiplimab RWLC, Cemiplimab-rwlc, Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Libtayo, REGN2810, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy
Mayo Clinic, National Cancer Institute (NCI)
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
12/28
04/32
NCI10208, NCT03816358: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Active, not recruiting
1
74
Canada, US
Anetumab Ravtansine, BAY 94-9343, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
01/25
01/25
NCT04840615: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

Terminated
1
2
US
LMB-100, ipilimumab, Yervoy, Diphenhydramine, Benadryl, Famotidine, Pepcid, Acetaminophen, Tylenol, Dexamethasone, Ozurdex, Biopsy, FDG-PET, Fluorodeoxyglucose-positron emission tomography, CT CAP, Computed tomography of the chest, abdomen and pelvis, MRI, Magnetic resonance imaging, ECG, Electrocardiogram, Echocardiogram, Echo
National Cancer Institute (NCI)
Mesothelioma
12/21
01/22
PRIMO, NCT04270864: Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Active, not recruiting
1
72
Europe
Ipilimumab, Nivolumab, Tilsotolimod
Gustave Roussy, Cancer Campus, Grand Paris
Advanced Cancer
02/24
02/26
NCT01738139: Ipilimumab and Imatinib Mesylate in Advanced Cancer

Completed
1
68
US
Imatinib Mesylate, CGP 57148, CGP57148B, Gleevec, Glivec, STI 571, STI-571, STI571, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Gastrointestinal Stromal Tumor, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma, Unresectable Solid Neoplasm
12/22
12/23
PERFORM, NCT04163289: Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation

Active, not recruiting
1
20
Canada
Fecal Microbiota Transplantation
Lawson Health Research Institute, Academic Medical Organization of Southwestern Ontario
Renal Cell Carcinoma
11/23
11/28
NCT04323046: Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

Recruiting
1
20
Europe, US, RoW
Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Sabine Mueller, MD, PhD, Pacific Pediatric Neuro-Oncology Consortium
Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma, Grade III Glioma
03/26
03/29
HAMMER I, NCT05169957: Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial

Active, not recruiting
1
2
US
Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy, SBRT
University of Michigan Rogel Cancer Center
Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal, Liver Metastases
06/23
06/25
NCT05700461: Drug Screening Using Novel IMD in Renal Cell Carcinoma

Recruiting
1
5
US
Implantable Microdevice (IMD)
Wenxin Xu
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer
03/24
03/26
NCT05498792: Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Suspended
1
12
US
CBL0137, Curaxin, Ipilimumab, Nivolumab
Fox Chase Cancer Center, Incuron
Locally Advanced or Metastatic Melanoma
03/25
09/25
NCT05341349: Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Recruiting
1
10
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Tumor Treating Fields Therapy, Alternating Electric Field Therapy, TTF, TTFields
Emory University, National Cancer Institute (NCI), NovoCure Ltd.
Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Ocular Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
03/25
03/25
NCT03600155: Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Active, not recruiting
1
29
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
03/26
03/26
NCT05254184: KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC

Recruiting
1
12
US
Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides, Nivolumab 3 mg/kg every 2 weeks, Ipilimumab 1 mg/kg every 6 weeks
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
04/25
04/27
ENVOY-001, NCT04892043: Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1
5
US
SQZ-AAC-HPV, Ipilimumab, Nivolumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
NCT06414642: Dose Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab in Advanced Stage Renal Cell Carcinoma

Recruiting
1
28
US
CBM588 Capsules, CBM588, Clostridium butyricum MIYAIRI 588, Live Biotherapeutic Product (LBP), Nivolumab, Opdivo, MDX-1106/ONO-4538, Ipilimumab, Yervoy, MDX010
Osel, Inc., City of Hope Comprehensive Cancer Center, Miyarisan Pharmaceutical Co., Ltd.
Advanced or Metastatic Renal Cell Carcinoma
04/26
07/26
NCT04388852: DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Recruiting
1
80
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Valemetostat, DS 3201, DS-3201, DS3201
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
12/26
12/26
NCT04141644: Phase Ib Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Active, not recruiting
1
24
US
Ipilimumab, Bristol-Myers Squibb (BMS)-734016, Medarex (MDX)-010, Yervoy, Osimertinib, Tagrisso
University of Utah
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
04/25
04/28
NCT05358938: Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Active, not recruiting
1
22
US
Exercise, Checkpoint Blockade, Immune, Avelumab, Cemiplimab, Ipilimumab, Nivolumab, Pembrolizumab
H. Lee Moffitt Cancer Center and Research Institute
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
10/24
10/24
NCT06295159: Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

Recruiting
1
90
US
Nivolumab, Opdivo, Nivolumab + Relatlimab, Opdualag, Ipilimumab, Yervoy
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
03/27
03/27
NCT03912064: A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Active, not recruiting
1
25
US
Ipilimumab, Yervoy, CD25hi Treg depleted DLI
Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis
05/24
07/25
NCT06514651: MAQ-001 in Patients With Advanced Solid Tumors

Recruiting
1
30
Europe
MAQ-001, Ipilimumab, Yervoy
MabQuest SA
Advanced Solid Tumor
06/26
06/28
NCT06399419: CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Recruiting
1
28
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, CBM588 Capsules, CBM588, Clostridium butyricum MIYAIRI 588, C. butyricum MIYAIRI 588, C. butyricum strain MIYAIRI 588, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Osel, Inc., City of Hope Medical Center, Miyarisan Pharmaceuticals, Co., Ltd., National Cancer Institute (NCI)
Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
10/26
10/26
NCT02408861: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Terminated
1
95
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anal Carcinoma, HIV Infection, Kaposi Sarcoma, Lung Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Unresectable Solid Neoplasm
05/24
08/24
NCT02890329: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Active, not recruiting
1
54
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy
National Cancer Institute (NCI)
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
10/22
08/25
NCT03502733: Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Active, not recruiting
1
64
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Copanlisib, BAY 80 6946, BAY 80-6946, BAY 806946, BAY-80-6946, BAY806946, PI3K Inhibitor BAY 80-6946, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
07/24
07/24
ANV419-001, NCT04855929: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.

Recruiting
1
80
Europe
ANV419, Ipilimumab
Anaveon AG
Advanced Solid Tumor, Adult Disease, Lung Cancer
09/24
01/25
NCT04967196: Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Active, not recruiting
1
6
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Lymph Node Assessment, Lymph Node Examination, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
Mayo Clinic
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
07/24
07/25
NCT05088889: Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Recruiting
1
10
RoW
Nivolumab, ipilimumab, Stereotactic body radiation therapy, SBRT, Low dose irradiation
Sheba Medical Center, Bristol-Myers Squibb
Stage IV Pancreatic Cancer
07/24
07/24
NCT03690986: VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Recruiting
1
50
US
VX15/2503, moAb VX15/2503, Anti-SEMA4D Monoclonal Antibody VX15/2503, Pepinemab, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
Emory University, Vaccinex Inc.
Squamous Cell Carcinoma of the Head and Neck
07/24
07/25
iFOCUS, NCT06524570: Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy

Recruiting
1
24
Europe
HIFU-HT, ICI, Immune checkpoint inhibitors
UMC Utrecht
Cancer, Metastatic Cancer
08/30
08/30
NCT03463408: Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma

Active, not recruiting
1
14
US
nivolumab, ipilimumab
University of Rochester
Sarcoma
08/24
08/25
NCT04495257: A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Active, not recruiting
1
26
US
Nivolumab, Ipilimumab, APX005M
Yale University, Apexigen America, Inc.
Advanced Melanoma, Renal Cell Carcinoma
08/24
02/25
NCT06377111: A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma

Recruiting
1
12
Canada
C-PAN, Calcium Pantothenate, Vitamin B5, Nivolumab, anti-PD-1 antibody, Ipilimumab, anti-CLTA-4 antibody
University Health Network, Toronto
Melanoma (Skin)
08/26
08/26
PERIO-01, NCT04935229: Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Active, not recruiting
1
80
US
SD-101, Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab and Relatlimab, Opdualag
TriSalus Life Sciences, Inc.
Metastatic Uveal Melanoma in the Liver
09/24
01/25
NCT06324240: Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Not yet recruiting
1
18
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Vaccine Therapy
Emory University, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
12/26
12/26
NCT02496208: Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

Checkmark Data in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory metastatic GU tumors
Feb 2021 - Feb 2021: Data in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory metastatic GU tumors
Checkmark Data from CaboNivo trial for genitourinary tumors at ESMO 2017 [screenshot]
Sep 2017 - Sep 2017: Data from CaboNivo trial for genitourinary tumors at ESMO 2017 [screenshot]
Checkmark Urothelial carcinoma and other genitourinary tumors
More
Active, not recruiting
1
152
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Sarcomatoid Urothelial Carcinoma, Kidney Medullary Carcinoma, Malignant Genitourinary System Neoplasm, Malignant Solid Neoplasm, Penile Carcinoma, Penile Squamous Cell Carcinoma, Renal Cell Carcinoma, Renal Pelvis Urothelial Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage III Renal Pelvis and Ureter Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Ureter Urothelial Carcinoma, Urethral Urothelial Carcinoma
09/24
09/24
REVOLUTION, NCT04787991: Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Active, not recruiting
1
45
US
Nivolumab (Cohort A), Opdivo, Ipilimumab (Cohort A, B and C), Yervoy, Hydroxychloroquine (HCQ) (Cohort B), Plaquenil, Nab-paclitaxel (nP) (Cohort A, B and C), Abraxane, Gemcitabine (gem) (Cohort A, B and C), Gemzar, NG350A (Cohort C)
Cancer Insight, LLC, Bristol-Myers Squibb, Cancer Research Institute, New York City, Akamis Bio
Metastatic Pancreatic Adenocarcinoma
10/24
01/25
NCT03017820: VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Recruiting
1
120
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Oncolytic VSV-hIFNbeta-NIS, Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Voyager-V1, VSV-expressing hIFNb and NIS, VSV-hIFNb-NIS, VSV-hIFNbeta-NIS, VV1, Single Photon Emission Computed Tomography, Medical Imaging, Single Photon Emission Computed Tomography, Single Photon Emission Tomography, Single-Photon Emission Computed, single-photon emission computed tomography, SPECT, SPECT imaging, SPECT SCAN, SPET, ST, tomography, emission computed, single photon, Tomography, Emission-Computed, Single-Photon, Cemiplimab, 1801342-60-8, Cemiplimab RWLC, Cemiplimab-rwlc, Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Disulfide with Human Monoclonal REGN2810 kappa-chain, Libtayo, REGN2810
Mayo Clinic, National Cancer Institute (NCI)
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
12/28
04/32
DUET-3, NCT03752398: A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

Calendar Jan 2024 - Dec 2024: From DUET-3 trial for advanced solid tumors
Completed
1
198
US
XmAb®23104, Yervoy® (ipilimumab)
Xencor, Inc., ICON plc
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
02/24
02/24
NCT05188118: Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma

Recruiting
1
20
US
Cabozantinib, Ipilimumab, Nivolumab, Lenvatinib, Everolimus
Icahn School of Medicine at Mount Sinai
Renal Cell Carcinoma
12/25
12/25
IRB00210915, NCT04117087: Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Recruiting
1
30
US
KRAS peptide vaccine, Hiltonol® (Poly-ICLC), Nivolumab, OPDIVO, Ipilimumab, YERVOY®
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb, National Cancer Institute (NCI), National Institutes of Health (NIH)
Colorectal Cancer, Pancreatic Cancer
08/25
08/25
NCI-2015-00693, NCT02419495: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies

Terminated
1
221
US
Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Eribulin, ER-086526, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Irinotecan Hydrochloride, Campto, Camptosar, Camptothecin 11, Camptothecin-11, CPT 11, CPT-11, Irinomedac, Irinotecan Hydrochloride Trihydrate, Irinotecan Monohydrochloride Trihydrate, U-101440E, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Selinexor, ATG-010, CRM1 Nuclear Export Inhibitor KPT-330, KPT-330, Selective Inhibitor of Nuclear Export KPT-330, SINE KPT-330, Xpovio, Topotecan, Hycamptamine, Topotecan Lactone
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Ovarian Carcinoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Primary Peritoneal Carcinoma, Stage III Lung Cancer AJCC V8, Stage III Renal Cell Cancer AJCC V8, Stage IIIA Lung Cancer AJCC V8, Stage IIIB Lung Cancer AJCC V8, Stage IIIC Lung Cancer AJCC V8, Stage IV Lung Cancer AJCC V8, Stage IV Renal Cell Cancer AJCC V8, Stage IVA Lung Cancer AJCC V8, Stage IVB Lung Cancer AJCC V8, Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Unresectable Renal Cell Carcinoma
09/24
09/24
NCT02950766: NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active, not recruiting
1
19
US
NeoVax, neoantigen vaccine, Ipilimumab, Yervoy
Patrick Ott, MD, PhD, Bristol-Myers Squibb, Oncovir, Inc.
Kidney Cancer
12/24
09/26
NCT04013542: Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer

Active, not recruiting
1
21
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
ALK Gene Rearrangement, EGFR Gene Mutation, Locally Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
12/24
12/24
NCT04781855: Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Active, not recruiting
1
50
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
12/24
12/24
NCT04399876: Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate Cancer

Enrolling by invitation
1
35
US
Microdevice
Brigham and Women's Hospital, National Cancer Institute (NCI)
Prostate Cancer, Radical Prostatectomy
03/25
03/26
IT-IO, NCT05598853: Intrathecal Double Checkpoint Inhibition

Recruiting
1
26
Europe
intrathecal nivolumab and intrathecal ipilimumab
University of Zurich
Leptomeningeal Metastasis, Non-small Cell Lung Cancer Stage IV, Melanoma Stage IV
04/25
04/25
NCT03508570: Nivolumab with or Without Ipilimumab in Treating Patients with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis

Active, not recruiting
1
26
US
Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pharmacokinetic Study, PHARMACOKINETIC, PK Study
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Peritoneal Carcinomatosis, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Malignant Female Reproductive System Neoplasm, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC V8, Stage IV Ovarian Cancer AJCC V8, Stage IV Primary Peritoneal Cancer AJCC V8, Stage IVA Fallopian Tube Cancer AJCC V8, Stage IVA Ovarian Cancer AJCC V8, Stage IVA Primary Peritoneal Cancer AJCC V8, Stage IVB Cervical Cancer AJCC V8, Stage IVB Fallopian Tube Cancer AJCC V8, Stage IVB Ovarian Cancer AJCC V8, Stage IVB Primary Peritoneal Cancer AJCC V8, Stage IVB Uterine Corpus Cancer AJCC V8
04/25
04/25
CheckVAC, NCT05721846: Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer

Recruiting
1
20
Europe
Nivolumab, Ipilimumab, SBRT, TGFβ-B-15 peptide
Inna Chen, MD
Pancreatic Cancer
05/25
12/25
NCT02668770: Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Checkmark Enrollment completion of P1 combinational trial with ipilimumab
Jul 2020 - Jul 2020: Enrollment completion of P1 combinational trial with ipilimumab
Hourglass Jan 2019 - Dec 2019 : In combination with Yervoy for advanced solid malignances
Hourglass Jan 2017 - Dec 2018 : Completion of recruitment (advanced solid malignancies)
Hourglass Sep 2018 - Dec 2018 : Completion of dose escalation portion of P1 trial for advanced solid malignancies
More
Active, not recruiting
1
28
US
MGN1703, Ipilimumab, BMS-734016, Yervoy, MDX010
M.D. Anderson Cancer Center, Mologen AG
Advanced Cancers, Melanoma
05/25
05/25
 

Download Options